Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two nonsteroidal anti-inflammatory drugs (NSAIDs). Meloxicam is a prescription NSAID that selectively inhibits COX-2 enzymes, while aspirin (acetylsalicylic acid) is an NSAID that inhibits both COX-1 and COX-2 enzymes. When taken together, these medications can interact with each other. According to the search results, concurrent treatment with aspirin can increase plasma concentrations of meloxicam, raising the maximum plasma concentration (Cmax) by approximately 25% and the area under the plasma concentration-time curve (AUC) by 10%[3]. However, these differences were not considered clinically relevant, and no adjustments of meloxicam dose should be required when coadministered with aspirin[3]. Both medications are used to treat pain and inflammation, but they have different properties. Meloxicam is primarily used for osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis[7]. Aspirin, besides its anti-inflammatory effects, also has antiplatelet properties that make it beneficial for preventing heart attacks and strokes, which meloxicam does not offer[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + meloxicam.